<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Anticoagulation for continuous kidney replacement therapy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Anticoagulation for continuous kidney replacement therapy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Anticoagulation for continuous kidney replacement therapy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Davenport, MD, FRCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steve J Schwab, MD, FACP, FASN
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul M Palevsky, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 13, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H110623180">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kidney replacement therapy (KRT) is commonly required in patients with severe acute kidney injury (AKI). Continuous kidney replacement therapy (CKRT) is an alternative to an intermittent therapy such as standard hemodialysis.
        </p>
        <p>
         CKRT may require anticoagulation to prevent clotting of the extracorporeal circuits, although CKRT without anticoagulation is often attempted [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         This topic reviews strategies to prevent clotting and approaches to anticoagulation for patients on CKRT. Other issues related to CKRT are discussed elsewhere (see
         <a class="medical medical_review" href="/z/d/html/1845.html" rel="external">
          "Continuous kidney replacement therapy in acute kidney injury"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1932.html" rel="external">
          "Drug removal in continuous kidney replacement therapy"
         </a>
         ). Anticoagulation for patients on intermittent hemodialysis is provided elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1840.html" rel="external">
          "Anticoagulation for the hemodialysis procedure"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1737971268">
         <span class="h1">
          INDICATIONS AND RATIONALE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anticoagulation is used to prevent clotting of the extracorporeal system. Clotting of the circuit may be minor, leading to clotting in the capillary fibers and reduced solute clearances, or major, leading to loss of the hemofilter, tubing, and blood in the circuit [
         <a href="#rid2">
          2,3
         </a>
         ]. Replacing the hemofilter and tubing interrupts CKRT and reduces the total therapy time. Studies have shown that interruptions from clotting may reduce the total time on CKRT from 24 to 16 hours per day [
         <a href="#rid4">
          4,5
         </a>
         ]. Such reductions reduce the effectiveness of CKRT. A sufficient operating time is required to ensure that an adequate KRT dose is delivered.
        </p>
        <p>
         However, anticoagulation increases the complexity and cost of the procedure. At our center, we perform CKRT without anticoagulation, providing filter life can be maintained for &gt;24 hours. We use anticoagulation if the filter life cannot be maintained for &gt;24 hours. However, some centers routinely use anticoagulation from the start in order to prevent clotting, and the Kidney Disease Improving Global Outcomes (KDIGO) guidelines suggest the use of anticoagulation [
         <a href="#rid6">
          6
         </a>
         ]. However, a Cochrane systematic review concluded that the most effective anticlotting options for CKRT remain to be determined [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2680917799">
         <span class="h1">
          AVAILABLE ANTICOAGULANT THERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most commonly used options for CKRT anticoagulation include regional citrate (RCA) and
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Low-molecular-weight heparin (LMWH), thrombin antagonists (
         <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">
          argatroban
         </a>
         and
         <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">
          bivalirudin
         </a>
         ), UFH with protamine reversal, heparinoids, platelet-inhibiting agents, and heparin surface-coated hemofilters are less common options.
        </p>
        <p class="headingAnchor" id="H1685403808">
         <span class="h2">
          Regional citrate anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         RCA decreases the rate of clotting and may be used in all CKRT modalities [
         <a href="#rid9">
          9-18
         </a>
         ]. Compared with systemic heparin, RCA reduces the risks of bleeding [
         <a href="#rid9">
          9,15,19-22
         </a>
         ]. (See
         <a class="local">
          'Preferential use of regional citrate anticoagulation'
         </a>
         below.)
        </p>
        <p>
         During RCA, sodium citrate is infused into the inflow ("arterial") limb of the extracorporeal circuit, chelating calcium and inhibiting clotting. The majority of the
         <a class="drug drug_general" data-topicid="8829" href="/z/d/drug information/8829.html" rel="external">
          calcium citrate
         </a>
         complex is removed across the hemofilter. Any calcium citrate complex that remains postfilter is returned to the patient and indirectly metabolized to bicarbonate by the liver, kidney, and skeletal muscle. Regional anticoagulation is reversed by dilution of citrate in the extracellular compartment and by its rapid metabolic clearance [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         A systemic calcium infusion is required to replace the calcium that is lost in the effluent in order to maintain a normal ionized serum calcium concentration.
        </p>
        <p>
         The use of RCA may require modification of the composition of dialysate or replacement fluid. The concentration of buffers (eg, bicarbonate, lactate) should be reduced to prevent alkalosis since citrate provides alkali. In addition, citrate can also bind magnesium and, therefore, we prefer dialysates or replacement fluid solutions that have 0.75 mmol/L rather than 0.5 mmol/L of magnesium.
        </p>
        <p>
         Ideally, the dialysate and replacement fluids should also be calcium free to prevent reversal of the citrate effect in the extracorporeal circuit, although this is not absolutely necessary. If calcium-containing replacement fluid is used, more citrate is required to chelate calcium in both the blood and replacement fluid, but a separate calcium reinfusion may not be required.
        </p>
        <p>
         RCA use for CKRT is not approved by the US Food and Drug Administration (FDA). The absence of a US FDA-approved citrate regimen has been a barrier to use of citrate regimens in the United States. Some institutional pharmacies have been unwilling to permit off-label use of citrate.
        </p>
        <p class="headingAnchor" id="H3681763513">
         <span class="h2">
          Unfractionated heparin
         </span>
         <span class="headingEndMark">
          —
         </span>
         UFH is widely used for CKRT [
         <a href="#rid24">
          24
         </a>
         ], particularly in the many institutions that do not have the ability to use RCA [
         <a href="#rid25">
          25-27
         </a>
         ]. UFH is effective, inexpensive, and widely available [
         <a href="#rid25">
          25-27
         </a>
         ].
        </p>
        <p>
         However, there are disadvantages associated with the use of UFH, including unpredictable and complex pharmacokinetics that result in dosing variability, the development of heparin-induced thrombocytopenia (HIT), heparin resistance due to low patient antithrombin levels, and an increased risk of bleeding [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/90261.html" rel="external">
          "Clinical presentation and diagnosis of heparin-induced thrombocytopenia"
         </a>
         .)
        </p>
        <p>
         The reported incidence of bleeding ranges from 10 to 50 percent and is related to the degree of prolongation of the activated partial thromboplastin time (aPTT) [
         <a href="#rid3">
          3,29,30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1895931479">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other approaches include UFH with protamine reversal, low-molecular-weight heparins, thrombin antagonists,
         <a class="drug drug_general" data-topicid="9320" href="/z/d/drug information/9320.html" rel="external">
          danaparoid
         </a>
         , nafamostat maleate, prostacyclin and other prostanoids, and platelet-inhibiting agents [
         <a href="#rid31">
          31-51
         </a>
         ].
        </p>
        <p>
         We do not routinely use these agents, because there are insufficient data that have demonstrated benefit, and their safety among CKRT patients has not been adequately studied.
        </p>
        <p class="headingAnchor" id="H110623189">
         <span class="h1">
          OUR APPROACH
         </span>
        </p>
        <p class="headingAnchor" id="H3452340191">
         <span class="h2">
          Initial approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients, we attempt CKRT without anticoagulation. We usually can achieve adequate CKRT filter survival without anticoagulation, providing the patient has a well-functioning vascular access [
         <a href="#rid52">
          52-55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/113966.html" rel="external">
          "Prescription of continuous kidney replacement therapy in acute kidney injury in adults", section on 'Vascular access'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113966.html" rel="external">
          "Prescription of continuous kidney replacement therapy in acute kidney injury in adults", section on 'CKRT blood flow rate'
         </a>
         .)
        </p>
        <p>
         The following strategies may prolong hemofilter survival in the absence of anticoagulation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maintain adequate blood flow ─
         </strong>
         We try to maintain blood flow between 100 to 300 mL/min. Very low blood flows are a common cause of circuit clotting because they increase the risk of stasis and increase the filtration fraction, which causes hemoconcentration across the hemofilter [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/113966.html" rel="external">
          "Prescription of continuous kidney replacement therapy in acute kidney injury in adults", section on 'Filtration fraction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However a higher blood flow (ie, &gt;300 mL/min) may also cause clotting by triggering pressure alarms that stop the blood flow and cause stasis. Even in the absence of clotting, very high blood flows limit the lifespan of the extracorporeal circuit tubing and hemofilter because they can only process a finite volume of blood before the tubing starts to degrade. (See
         <a class="medical medical_review" href="/z/d/html/113966.html" rel="external">
          "Prescription of continuous kidney replacement therapy in acute kidney injury in adults", section on 'CKRT blood flow rate'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minimize hemoconcentration within the hemofilter ─
         </strong>
         Hemoconcentration refers to the increasing concentration of red blood cells, platelets, and coagulation factors in blood. The risk of clotting may be increased by hemoconcentration within the hemofilter, which occurs as a result of ultrafiltration (ie, the removal of water across the hemofilter).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We minimize hemoconcentration with the hemofilter by the following approach:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We administer predilution rather than postdilution replacement fluid. For convective therapies, such as continuous venovenous hemofiltration (CVVH), giving fluid before the hemofilter (ie, predilution replacement) decreases hemoconcentration within the hemofilter.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We keep the filtration fraction &lt;20 to 25 percent. Filtration fraction is the fraction of plasma water that is removed from blood during ultrafiltration. Higher filtration fractions are associated with increased circuit clotting, presumably from hemoconcentration and blood protein-membrane interactions [
         <a href="#rid57">
          57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/113966.html" rel="external">
          "Prescription of continuous kidney replacement therapy in acute kidney injury in adults", section on 'Filtration fraction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We also use
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         flushes, although there are no data that show that this decreases clotting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hemoconcentration may also be decreased by the use of diffusive therapies (such as continuous venovenous hemodialysis [CVVHD]) and continuous venovenous hemodiafiltration (CVVHDF) rather than postdilutional convective therapies (such as CVVH). (See
         <a class="medical medical_review" href="/z/d/html/1845.html" rel="external">
          "Continuous kidney replacement therapy in acute kidney injury", section on 'Definition of CKRT modality'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some studies have suggested that CVVH is associated with increased hemofilter clotting, believed to be related to the high ultrafiltration rate required for adequate CVVH [
         <a href="#rid58">
          58
         </a>
         ]. In addition to clotting within the hemofilter, clotting also occurs with blood-air interfaces. As such, careful priming of the extracorporeal circuit and adding
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         to the drip chamber such that there is a layer of saline above the blood level may minimize blood-air contact.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          React promptly to alarms
         </strong>
         – Alarms are triggered by increases in pressure, which are generally associated with blood stasis. Slow reaction allows the stasis to persist longer and leads to clotting [
         <a href="#rid24">
          24,57,59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reduce the blood-air contact in the drip chamber
         </strong>
         – Contact between blood and air increases platelet activation, which may cause clotting [
         <a href="#rid60">
          60
         </a>
         ]. Blood-air contact can be minimized by adding
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         to the drip chamber such that there is a layer of saline above the blood level [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoiding overheating dialysate and replacement solutions
         </strong>
         – Cooling of replacement solution below normothermia has been shown to improve patency in animal studies [
         <a href="#rid61">
          61,62
         </a>
         ]. While it is not clinically feasible to lower the temperature of replacement fluid below normal, we are careful not to overheat the solution.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoiding mechanical obstruction of blood lines
         </strong>
         – When moving patients, care should be taken not to kink lines and to ensure that lines are clearly visible.
        </p>
        <p>
        </p>
        <p>
         If there is repeated clotting, the first step is to ensure that the vascular access is functioning adequately.
        </p>
        <p class="headingAnchor" id="H3447021295">
         <span class="h2">
          Patients with repeated clotting of hemofilter
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the hemofilter cannot be maintained without anticoagulation for at least 24 hours, we use anticoagulation unless the clotting is due to access problems.
        </p>
        <p>
         If
         <a class="drug drug_general" data-topicid="115978" href="/z/d/drug information/115978.html" rel="external">
          regional citrate anticoagulation
         </a>
         (RCA) is available and the patient has no contraindications, we use RCA rather than
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH). RCA is effective and increases the hemofilter lifespan and lowers the bleeding risk and transfusion requirement compared with UFH [
         <a href="#rid9">
          9,15,19-22
         </a>
         ].
        </p>
        <p>
         For patients who have contraindications or do not tolerate RCA, or if RCA is not available, UFH may be used.
        </p>
        <p>
         Multiple randomized trials [
         <a href="#rid9">
          9,10,15,16,18-21,63-76
         </a>
         ] and meta-analyses [
         <a href="#rid22">
          22,77,78
         </a>
         ] have shown that RCA is better than heparin at preserving filter patency and has a lower risk of adverse events, including bleeding. There does not appear to be a survival benefit of either heparin or RCA [
         <a href="#rid9">
          9,78
         </a>
         ]. The largest meta-analysis (11 randomized trials, 992 patients) compared RCA with either systematic (nine trials) or regional (two trials) heparin [
         <a href="#rid78">
          78
         </a>
         ]. The risk of circuit loss was lower with RCA compared with regional heparin (hazard ratio [HR] 0.52, 95% CI 0.35-0.77) and systemic heparin (HR 0.76, 95% CI 0.59-0.98). The risk of bleeding was lower with RCA compared with systemic heparin (relative risk [RR] 0.36, 95% CI 0.21-0.60) and similar between RCA and regional heparin. There was no difference in survival between groups. However, another meta-analysis that included different studies reported no overall advantage for citrate in terms of circuit clotting but reported a reduction in major bleeding associated with RCA as compared with
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (RR 0.22, 95% CI 0.08-0.62) [
         <a href="#rid7">
          7
         </a>
         ]. In a subsequent large trial, compared with systemic heparin, RCA led to a prolonged filter life span but a higher frequency of new infections [
         <a href="#rid9">
          9
         </a>
         ]. Consistent with prior studies, there was no difference in survival between groups. Similarly, a report from the United Kingdom found no overall difference in survival with RCA compared with UFH and only a marginal difference in bleeding events [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         Citrate anticoagulation is not approved by the US Food and Drug Administration (FDA) for CKRT; commercial solutions for citrate anticoagulation for CKRT are not available in the United States [
         <a href="#rid80">
          80,81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2471169903">
         <span class="h3">
          Preferential use of regional citrate anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanism by which citrate works is described above [
         <a href="#rid10">
          10-16,18-21,63-76,82
         </a>
         ]. (See
         <a class="local">
          'Regional citrate anticoagulation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2846972685">
         <span class="h4">
          Method
         </span>
         <span class="headingEndMark">
          —
         </span>
         We use a blood flow rate of 80 to 200 mL/min. In contrast to patients who are not receiving any anticoagulation, higher blood flows are not required to prevent clotting. In addition, higher blood flows are counterproductive since the amount of required citrate increases with higher blood flows.
        </p>
        <p>
         A variety of methods of RCA have been described [
         <a href="#rid10">
          10-16,18-21,63-76,82
         </a>
         ]. In all, citrate solution is infused into the blood at the beginning of the extracorporeal circuit. In the United States, the citrate solution that is used for anticoagulation may need to be custom made by the hospital pharmacy, although in Europe and other countries, citrate preparations and dialysates are commercially available. Commercially available replacement and dialysate solutions that have been specifically designed for CKRT include Prismocitrate 10/2, which contains 10 mm/L citrate, 2 mmol/L citric acid, and 136 mmol/L sodium; Prismocitrate 18/0, which contains 18 mmol/L citrate; and calcium-free dialysates (Ci-Ca dialysate).
        </p>
        <p>
         Some centers may use commercially available citrate solutions that were not designed for CKRT and have high concentrations of citrate and sodium. Depending upon the concentration of citrate solution used and the corresponding sodium load, compensatory hyponatremic replacement and/or dialysate solutions with either no or reduced bicarbonate concentrations may be required to prevent the development of electrolyte abnormalities. (See
         <a class="medical medical_review" href="/z/d/html/113966.html" rel="external">
          "Prescription of continuous kidney replacement therapy in acute kidney injury in adults", section on 'CKRT solutions'
         </a>
         .)
        </p>
        <p>
         A separate calcium infusion is delivered to the patient and titrated to keep the systemic ionized calcium concentration in normal range. The citrate infusion rate is adjusted to keep the ionized calcium concentration in the extracorporeal circuit &lt;0.35 mmol/L (measured as the postfilter ionized calcium concentration), which correlates with citrate blood concentration of 4 to 6 mmol/L. It is important that the analyzer is calibrated to measure these low ionized calcium values [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9186" href="/z/d/drug information/9186.html" rel="external">
          Calcium chloride
         </a>
         or
         <a class="drug drug_general" data-topicid="9190" href="/z/d/drug information/9190.html" rel="external">
          calcium gluconate
         </a>
         is infused into the venous return line at an initial rate of 2 to 3 mmol/hour to replace calcium lost in the effluent when using calcium-free dialysate and replacement fluids. The rate is adjusted according to measurements of plasma calcium concentration to prevent hypocalcemia or hypercalcemia [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Citrate-based anticoagulation can also be used among patients receiving CVVHD  (
         <a class="graphic graphic_table graphicRef128046" href="/z/d/graphic/128046.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1103146952">
         <span class="h4">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not use RCA, at least initially, in patients who are likely to have impaired metabolic clearance of citrate:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute liver failure with blood transaminases values &gt;1000 international unit/L ─
         </strong>
         This is usually from ischemia (ie, shock liver) but could be related to hepatitis from any cause. Such patients are unlikely to metabolize citrate appropriately, resulting in severe acidosis and decreases in ionized calcium. However, we may attempt anticoagulation with RCA once liver function starts to improve.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiogenic shock with blood lactate values &gt;8 mmol/L ─
         </strong>
         Similar to patients with acute liver failure, such patients will not metabolize citrate. RCA may be used if there is clinical improvement and a decrease in lactate to ≤8 mmol/L.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3680671950">
         <span class="h4">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         We check blood electrolytes at least every six hours and include sodium, potassium, chloride, ionized calcium, magnesium, and blood gas analysis, along with calculation of the anion gap. At least once daily, total blood calcium concentration should be monitored to calculate the calcium ratio (total calcium/ionized calcium) or calcium gap (total calcium minus ionized calcium), which, if abnormal, may indicate citrate accumulation. Blood gas analyzers may need to be recalibrated to measure low-ionized calcium concentrations.
        </p>
        <p>
         The need for monitoring anticoagulation efficacy in the circuit depends on the method of citrate delivery. If the dose of citrate is fixed in relation to the blood flow, monitoring is not necessary as long as blood flow is constant. If the citrate dose is not fixed to a constant blood flow rate, postfilter ionized calcium levels should be measured at least every six hours and the infusion of citrate titrated for an ionized calcium &lt;0.35 mmol/L.
        </p>
        <p>
         Once steady state is reached after 48 to 72 hours and the patient remains stable, monitoring of electrolytes can be decreased to every 12 hours.
        </p>
        <p class="headingAnchor" id="H186193530">
         <span class="h4">
          Citrate accumulation and indications to stop RCA
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="115978" href="/z/d/drug information/115978.html" rel="external">
          Regional citrate anticoagulation
         </a>
         (RCA) should be stopped if there is citrate accumulation. It is difficult to predict which patients will develop citrate accumulation. Patients at very high risk are those with acute liver failure who have transaminases &gt;1000 international unit/L, those with acute on chronic liver failure [
         <a href="#rid85">
          85
         </a>
         ], and also those with cardiogenic shock and lactate concentrations &gt;8 mmol/L, although other causes of hyperlactatemia do not necessarily preclude the use of citrate [
         <a href="#rid86">
          86
         </a>
         ]. As noted above, we do not use RCA in such patients. (See
         <a class="local">
          'Our approach'
         </a>
         above.)
        </p>
        <p>
         Citrate accumulation is suggested by the following [
         <a href="#rid87">
          87-90
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Worsening metabolic acidosis with increasing anion gap
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreasing ionized calcium requiring escalating calcium infusion rates
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increasing total calcium
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A ratio of total calcium to ionized calcium &gt;2.5
        </p>
        <p>
        </p>
        <p>
         There is no absolute value or threshold that is used to stop RCA. We generally look at trends of all those criteria and stop RCA only when all criteria are met. Prior to stopping RCA, certain measures to reduce citrate accumulation can be tried, such as reducing the citrate infusion rate for patients on hemofiltration or increasing the dialysate infusion rate for patients on hemodialysis or hemodiafiltration.
        </p>
        <p>
         In general, we will stop RCA if serum bicarbonate levels continue to fall over several measurements with increasing anion gap, if the ratio of total calcium to ionized calcium exceeds 2.5 and does not respond to the above modifications, and if the calcium infusion rates exceeds 90 mL/hour. Since the calcium infusion is titrated according to ionized calcium levels, most patients do not develop significantly low ionized calcium levels. Positive calcium balance by excessive correction of hypocalcemia should be avoided among patients with severe rhabdomyolysis. (See
         <a class="medical medical_review" href="/z/d/html/839.html" rel="external">
          "Etiology of hypercalcemia", section on 'Rhabdomyolysis associated with acute renal failure'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4143896854">
         <span class="h4">
          Other complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The potential complications associated with regional citrate include hypocalcemia (ie, in absence of other evidence of citrate toxicity), hypercalcemia, hypernatremia, hypomagnesemia, and acid-base disorders [
         <a href="#rid15">
          15
         </a>
         ]. Either alkalosis or acidosis can occur [
         <a href="#rid91">
          91
         </a>
         ]. These are rarely indications to stop CKRT, providing acidosis is not accompanied by other evidence of citrate accumulation. (See
         <a class="local">
          'Citrate accumulation and indications to stop RCA'
         </a>
         above.)
        </p>
        <p>
         The rate of specific complications depends on the specific protocol used and on patient comorbidities. In a study of 133 patients treated with RCA, severe alkalosis (pH &gt;7.55) was present in approximately 2 percent of patients and severe hypocalcemia (ionized calcium ≤0.9 mmol/L) in approximately 11 percent [
         <a href="#rid91">
          91
         </a>
         ]. Hypercalcemia (ionized calcium ≥1.5) did not occur in this study.
        </p>
        <p>
         Alkalosis is less common when replacement solutions and dialysate solutions contain reduced bicarbonate concentrations. Solutions commonly used for patients who are not on RCA contain bicarbonate solution of 32 to 35 mEq/L, whereas solutions for patients treated with RCA contain bicarbonate concentration of 22 to 25 mEq/L. (See
         <a class="medical medical_review" href="/z/d/html/113966.html" rel="external">
          "Prescription of continuous kidney replacement therapy in acute kidney injury in adults", section on 'CKRT solutions'
         </a>
         .)
        </p>
        <p>
         As noted above, severe acidosis may develop if citrate is not metabolized by the liver or muscle (see
         <a class="local">
          'Citrate accumulation and indications to stop RCA'
         </a>
         above). However, acidosis may also develop in the absence of citrate accumulation [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H439495552">
         <span class="h3">
          Unfractionated heparin
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the patient requires anticoagulation and we cannot use RCA, we use UFH. We start with a loading dose of 500 to 1000 international units followed by infusion of 500 units per hour. We adjust the heparin infusion according to activated partial thromboplastin time (aPTT) or ratio (aPTTr).
        </p>
        <p>
         We target an aPTT of 45 seconds or aPTTr 1.5 times normal [
         <a href="#rid3">
          3,28-30,54,92,93
         </a>
         ]. The heparin dose should be reduced in patients with disseminated intravascular coagulation or thrombocytopenia.
        </p>
        <p class="headingAnchor" id="H2830854078">
         <span class="h3">
          Combined RCA and unfractionated heparin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="115978" href="/z/d/drug information/115978.html" rel="external">
          Regional citrate anticoagulation
         </a>
         (RCA) has not been shown to reduce platelet activation or thrombin generation in critically ill patients undergoing CKRT [
         <a href="#rid94">
          94
         </a>
         ]. As such, circuit clotting was increased with the first wave of coronavirus disease 2019 (COVID-19) infections, and therefore, many centers combined systemic heparin with RCA without observing an increase in bleeding complications [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1891293902">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110752.html" rel="external">
          "Society guideline links: Acute kidney injury in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H110623245">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Continuous kidney replacement therapy (CKRT) may require anticoagulation to prevent clotting in the extracorporeal system and loss of the hemofilter. Clotting decreases the total therapy time and efficacy. A sufficient time on CKRT is necessary to ensure an adequate KRT dose is delivered. (See
         <a class="local">
          'Indications and rationale'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients, we attempt CKRT without anticoagulation, although many clinicians use anticoagulation from the outset. We usually can achieve adequate CKRT filter survival if the patient has a well-functioning vascular access. Strategies to prolong hemofilter survival in the absence of anticoagulation are discussed. (See
         <a class="local">
          'Initial approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the hemofilter cannot be maintained without anticoagulation for at least 24 hours, we use anticoagulation. If
         <a class="drug drug_general" data-topicid="115978" href="/z/d/drug information/115978.html" rel="external">
          regional citrate anticoagulation
         </a>
         (RCA) is available and the patient has no contraindications, we use RCA rather than
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          unfractionated heparin
         </a>
         (UFH). RCA is better than heparin at preserving filter patency and is less likely to cause adverse events, including bleeding. However, RCA has not been shown to provide a survival benefit compared with heparin. (See
         <a class="local">
          'Patients with repeated clotting of hemofilter'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contraindications to RCA include acute liver failure with transaminases &gt;1000 units/L and cardiogenic shock with lactate values &gt;8 mmol/L. (See
         <a class="local">
          'Contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients on RCA should be closely monitored for evidence of citrate accumulation and other complications of CKRT. Our monitoring strategy is defined. (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior to stopping RCA for citrate toxicity, certain measures to reduce citrate accumulation can be tried, such as reducing the citrate infusion rate for patients on hemofiltration or increasing the dialysate infusion rate for patients on hemodialysis or hemodiafiltration. RCA should be stopped if these measures fail. Citrate accumulation is suggested by worsening metabolic acidosis, decreasing ionized calcium, and increasing total calcium. We stop RCA if serum bicarbonate levels continue to fall over several measurements with increasing anion gap, if the ratio of total calcium to ionized calcium exceeds 2.5, and if the calcium infusion rates exceeds 90 mL/hour. (See
         <a class="local">
          'Citrate accumulation and indications to stop RCA'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient requires anticoagulation and we cannot use RCA, we use UFH. Our protocol is defined. (See
         <a class="local">
          'Unfractionated heparin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H372978505">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge Ashita J Tolwani, MD, and Keith M Wille, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Schetz M. Anticoagulation in continuous renal replacement therapy. Contrib Nephrol 2001; :283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tolwani A. Continuous renal-replacement therapy for acute kidney injury. N Engl J Med 2012; 367:2505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van de Wetering J, Westendorp RG, van der Hoeven JG, et al. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996; 7:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkataraman R, Kellum JA, Palevsky P. Dosing patterns for continuous renal replacement therapy at a large academic medical center in the United States. J Crit Care 2002; 17:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luyckx VA, Bonventre JV. Dose of dialysis in acute renal failure. Semin Dial 2004; 17:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012; 2:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsujimoto H, Tsujimoto Y, Nakata Y, et al. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev 2020; 3:CD012467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial 2009; 22:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zarbock A, Küllmar M, Kindgen-Milles D, et al. Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA 2020; 324:1629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monchi M, Berghmans D, Ledoux D, et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38:976.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutsogiannis DJ, Mayers I, Chin WD, Gibney RT. Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis 2000; 35:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobe SW, Aujla P, Walele AA, et al. A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions. J Crit Care 2003; 18:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tolwani AJ, Campbell RC, Schenk MB, et al. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int 2001; 60:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67:2361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hetzel GR, Schmitz M, Wissing H, et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011; 26:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park JS, Kim GH, Kang CM, Lee CH. Regional anticoagulation with citrate is superior to systemic anticoagulation with heparin in critically ill patients undergoing continuous venovenous hemodiafiltration. Korean J Intern Med 2011; 26:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gattas DJ, Rajbhandari D, Bradford C, et al. A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults. Crit Care Med 2015; 43:1622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stucker F, Ponte B, Tataw J, et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Crit Care 2015; 19:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tolwani AJ, Prendergast MB, Speer RR, et al. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. Clin J Am Soc Nephrol 2006; 1:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Z, Hongying N. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 2012; 38:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Brecht JH, Flanigan MJ, Freeman RM, Lim VS. Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. Am J Kidney Dis 1986; 8:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nongnuch A, Tangsujaritvijit V, Davenport A. Anticoagulation for renal replacement therapy for patients with acute kidney injury. Minerva Urol Nefrol 2016; 68:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361:1627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med 2007; 33:1563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119:64S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 1994; 66:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin PY, Chevrolet JC, Suter P, Favre H. Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study. Am J Kidney Dis 1994; 24:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biancofiore G, Esposito M, Bindi L, et al. Regional filter heparinization for continuous veno-venous hemofiltration in liver transplant recipients. Minerva Anestesiol 2003; 69:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Voort PH, Gerritsen RT, Kuiper MA, et al. Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation. Blood Purif 2005; 23:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joannidis M, Kountchev J, Rauchenzauner M, et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Med 2007; 33:1571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Pont AC, Oudemans-van Straaten HM, Roozendaal KJ, Zandstra DF. Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. Crit Care Med 2000; 28:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray PT, Reddy BV, Grossman EJ, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 2004; 66:2446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy BV, Grossman EJ, Trevino SA, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother 2005; 39:1601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang IY, Cox DS, Patel K, et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2005; 39:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Link A, Girndt M, Selejan S, et al. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med 2009; 37:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiser TH, MacLaren R, Fish DN, et al. Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy. Pharmacotherapy 2010; 30:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindhoff-Last E, Betz C, Bauersachs R. Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients. Clin Appl Thromb Hemost 2001; 7:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langenecker SA, Felfernig M, Werba A, et al. Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Crit Care Med 1994; 22:1774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozek-Langenecker SA, Kettner SC, Oismueller C, et al. Anticoagulation with prostaglandin E1 and unfractionated heparin during continuous venovenous hemofiltration. Crit Care Med 1998; 26:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozek-Langenecker SA. Anticoagulation with prostaglandins during extracorporeal circulation. Wien Klin Wochenschr 1999; 111:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozek-Langenecker SA, Spiss CK, Gamsjäger T, et al. Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. Wien Klin Wochenschr 2002; 114:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiaccadori E, Maggiore U, Rotelli C, et al. Continuous haemofiltration in acute renal failure with prostacyclin as the sole anti-haemostatic agent. Intensive Care Med 2002; 28:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balik M, Waldauf P, Plásil P, Pachl J. Prostacyclin versus citrate in continuous haemodiafiltration: an observational study in patients with high risk of bleeding. Blood Purif 2005; 23:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohtake Y, Hirasawa H, Sugai T, et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol 1991; 93:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakae H, Tajimi K. Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane. Ther Apher Dial 2003; 7:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okada H, Suzuki H, Deguchi N, Saruta T. Agranulocytosis in a haemodialysed patient induced by a proteinase inhibitor, nafamostate mesilate. Nephrol Dial Transplant 1992; 7:980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ookawara S, Tabei K, Sakurai T, et al. Additional mechanisms of nafamostat mesilate-associated hyperkalaemia. Eur J Clin Pharmacol 1996; 51:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higuchi N, Yamazaki H, Kikuchi H, Gejyo F. Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient. Nephron 2000; 86:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellomo R, Parkin G, Love J, Boyce N. Use of continuous haemodiafiltration: an approach to the management of acute renal failure in the critically ill. Am J Nephrol 1992; 12:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morabito S, Guzzo I, Solazzo A, et al. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding. J Nephrol 2003; 16:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med 2000; 26:1652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uchino S, Fealy N, Baldwin I, et al. Continuous venovenous hemofiltration without anticoagulation. ASAIO J 2004; 50:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldwin I, Bellomo R, Koch B. Blood flow reductions during continuous renal replacement therapy and circuit life. Intensive Care Med 2004; 30:2074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joannidis M, Oudemans-van Straaten HM. Clinical review: Patency of the circuit in continuous renal replacement therapy. Crit Care 2007; 11:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricci Z, Ronco C, Bachetoni A, et al. Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Crit Care 2006; 10:R67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies H, Leslie G. Maintaining the CRRT circuit: non-anticoagulant alternatives. Aust Crit Care 2006; 19:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stefanidis I, Hägel J, Frank D, Maurin N. Hemostatic alterations during continuous venovenous hemofiltration in acute renal failure. Clin Nephrol 1996; 46:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krouzecky A, Chvojka J, Sykora R, et al. Regional cooling of the extracorporeal blood circuit: a novel anticoagulation approach for renal replacement therapy? Intensive Care Med 2009; 35:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagshaw SM, Davenport A. Cooling and reduced risk of clotting within the extracorporeal continuous renal replacement circuit. Intensive Care Med 2009; 35:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schilder L, Nurmohamed SA, Bosch FH, et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care 2014; 18:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brophy PD, Somers MJ, Baum MA, et al. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant 2005; 20:1416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta RL, McDonald BR, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis. An update after 12 months. Contrib Nephrol 1991; 93:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabutti L, Marone C, Colucci G, et al. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med 2002; 28:1419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagshaw SM, Laupland KB, Boiteau PJ, Godinez-Luna T. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care 2005; 20:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thoenen M, Schmid ER, Binswanger U, et al. Regional citrate anticoagulation using a citrate-based substitution solution for continuous venovenous hemofiltration in cardiac surgery patients. Wien Klin Wochenschr 2002; 114:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hofmann RM, Maloney C, Ward DM, Becker BN. A novel method for regional citrate anticoagulation in continuous venovenous hemofiltration (CVVHF). Ren Fail 2002; 24:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell A, Daul AE, Beiderlinden M, et al. A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD). Clin Nephrol 2003; 59:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgera S, Scholle C, Melzer C, et al. A simple, safe and effective citrate anticoagulation protocol for the genius dialysis system in acute renal failure. Nephron Clin Pract 2004; 98:c35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swartz R, Pasko D, O'Toole J, Starmann B. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol 2004; 61:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cointault O, Kamar N, Bories P, et al. Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions. Nephrol Dial Transplant 2004; 19:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Egi M, Naka T, Bellomo R, et al. A comparison of two citrate anticoagulation regimens for continuous veno-venous hemofiltration. Int J Artif Organs 2005; 28:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bihorac A, Ross EA. Continuous venovenous hemofiltration with citrate-based replacement fluid: efficacy, safety, and impact on nutrition. Am J Kidney Dis 2005; 46:908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naka T, Egi M, Bellomo R, et al. Low-dose citrate continuous veno-venous hemofiltration (CVVH) and acid-base balance. Int J Artif Organs 2005; 28:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu MY, Hsu YH, Bai CH, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2012; 59:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bai M, Zhou M, He L, et al. Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive Care Med 2015; 41:2098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gould DW, Doidge J, Sadique MZ, et al. Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study. Health Technol Assess 2022; 26:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palevsky PM, Liu KD, Brophy PD, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 2013; 61:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James M, Bouchard J, Ho J, et al. Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 2013; 61:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999; 55:1991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kindgen-Milles D, Ostermann M, Slowinski T. Ionized calcium measurements during regional citrate anticoagulation in CRRT: we need better blood gas analyzers. Crit Care 2015; 19:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgera S, Schneider M, Slowinski T, et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med 2009; 37:2018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thanapongsatorn P, Chaijamorn W, Sirivongrangson P, et al. Citrate pharmacokinetics in critically ill liver failure patients receiving CRRT. Sci Rep 2022; 12:1815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abstracts of the sixth International Conference on Experimental Ulcer. August 28-31, 1988, Jerusalem, Israel. Dig Dis Sci 1988; 33:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apsner R, Schwarzenhofer M, Derfler K, et al. Impairment of citrate metabolism in acute hepatic failure. Wien Klin Wochenschr 1997; 109:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003; 31:2450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meier-Kriesche HU, Gitomer J, Finkel K, DuBose T. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 2001; 29:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakker AJ, Boerma EC, Keidel H, et al. Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium. Clin Chem Lab Med 2006; 44:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slowinski T, Morgera S, Joannidis M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study. Crit Care 2015; 19:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellomo R, Teede H, Boyce N. Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Med 1993; 19:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leslie GD, Jacobs IG, Clarke GM. Proximally delivered dilute heparin does not improve circuit life in continuous venovenous haemodiafiltration. Intensive Care Med 1996; 22:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher R, Moore GW, Mitchell MJ, et al. Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study. Ann Intensive Care 2022; 12:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valle EO, Cabrera CPS, Albuquerque CCC, et al. Continuous renal replacement therapy in COVID-19-associated AKI: adding heparin to citrate to extend filter life-a retrospective cohort study. Crit Care 2021; 25:299.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16855 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11395897" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Anticoagulation in continuous renal replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23268665" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Continuous renal-replacement therapy for acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8808122" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12501152" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Dosing patterns for continuous renal replacement therapy at a large academic medical center in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14717809" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Dose of dialysis in acute renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : KDIGO Clinical Practice Guideline for Acute Kidney Injury
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32164041" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19426417" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Anticoagulation for continuous renal replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33095849" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14600809" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2266683" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10793012" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Regional citrate anticoagulation in continuous venovenous hemodiafiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12800123" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11422774" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Simplified citrate anticoagulation for continuous renal replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15882280" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20876598" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21437165" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Regional anticoagulation with citrate is superior to systemic anticoagulation with heparin in critically ill patients undergoing continuous venovenous hemodiafiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19114912" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Citrate anticoagulation for continuous venovenous hemofiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25853591" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25881975" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17699194" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22124775" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3752075" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Regional anticoagulation: hemodialysis with hypertonic trisodium citrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26473371" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Anticoagulation for renal replacement therapy for patients with acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19846848" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Intensity of continuous renal-replacement therapy in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18492867" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Intensity of renal support in critically ill patients with acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17594074" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11157643" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8015647" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7977323" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14564251" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Regional filter heparinization for continuous veno-venous hemofiltration in liver transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15711037" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17563874" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10708177" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15569338" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16131539" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15632219" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19050602" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Argatroban for anticoagulation in continuous renal replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20973685" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11697713" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7956281" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9671370" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Anticoagulation with prostaglandin E1 and unfractionated heparin during continuous venovenous hemofiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10192145" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Anticoagulation with prostaglandins during extracorporeal circulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12060975" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12029407" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Continuous haemofiltration in acute renal failure with prostacyclin as the sole anti-haemostatic agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16118487" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prostacyclin versus citrate in continuous haemodiafiltration: an observational study in patients with high risk of bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1666354" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14708904" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1328951" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Agranulocytosis in a haemodialysed patient induced by a proteinase inhibitor, nafamostate mesilate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8911880" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Additional mechanisms of nafamostat mesilate-associated hyperkalaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11096324" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1481871" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Use of continuous haemodiafiltration: an approach to the management of acute renal failure in the critically ill.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14696760" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11193272" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Continuous veno-venous hemofiltration without anticoagulation in high-risk patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14763495" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Continuous venovenous hemofiltration without anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15448889" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Blood flow reductions during continuous renal replacement therapy and circuit life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17634148" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Clinical review: Patency of the circuit in continuous renal replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16646985" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17165492" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Maintaining the CRRT circuit: non-anticoagulant alternatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8879856" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Hemostatic alterations during continuous venovenous hemofiltration in acute renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18802685" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Regional cooling of the extracorporeal blood circuit: a novel anticoagulation approach for renal replacement therapy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18841345" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Cooling and reduced risk of clotting within the extracorporeal continuous renal replacement circuit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25128022" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15855212" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1802583" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Regional citrate anticoagulation for continuous arteriovenous hemodialysis. An update after 12 months.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12373466" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16139156" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12060967" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Regional citrate anticoagulation using a citrate-based substitution solution for continuous venovenous hemofiltration in cardiac surgery patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12166699" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : A novel method for regional citrate anticoagulation in continuous venovenous hemofiltration (CVVHF).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12608553" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15361702" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : A simple, safe and effective citrate anticoagulation protocol for the genius dialysis system in acute renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14989634" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14671053" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16404696" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A comparison of two citrate anticoagulation regimens for continuous veno-venous hemofiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16253732" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Continuous venovenous hemofiltration with citrate-based replacement fluid: efficacy, safety, and impact on nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15818544" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Low-dose citrate continuous veno-venous hemofiltration (CVVH) and acid-base balance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22226564" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26482411" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35212260" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23499048" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23518195" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Canadian Society of Nephrology commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10231464" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26645989" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Ionized calcium measurements during regional citrate anticoagulation in CRRT: we need better blood gas analyzers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19384210" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35110648" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Citrate pharmacokinetics in critically ill liver failure patients receiving CRRT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3378484" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Abstracts of the sixth International Conference on Experimental Ulcer. August 28-31, 1988, Jerusalem, Israel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9076929" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Impairment of citrate metabolism in acute hepatic failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14530750" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11373461" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16879061" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26415638" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the Liver Citrate Anticoagulation Threshold (L-CAT) observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8227722" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9120123" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Proximally delivered dilute heparin does not improve circuit life in continuous venovenous haemodiafiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35355147" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34412667" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Continuous renal replacement therapy in COVID-19-associated AKI: adding heparin to citrate to extend filter life-a retrospective cohort study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
